Chapter 292 - 214: The Scramble for Wu Ting! A Special Meeting on His Promotion

Chapter 292: Chapter 214: The Scramble for Wu Ting! A Special Meeting on His Promotion

Dean Tang clearly hadn’t expected Wu Ting’s research project to be regarded so highly.

The Fan City Mother Fund was, after all, a national strategic industry fund, a synergistic fund for advantageous industries, and the only private equity fund in the Yangtze River Delta to be reviewed and named by the State Administration for Market Regulation.

Over its years of operation, the Fan City Fund had focused on pioneering industries like biomedicine, artificial intelligence, and integrated circuits. It covered more than ten cutting-edge fields, including third-generation semiconductors, gene sequencing, innovative pharmaceuticals, and information security. The fund aimed to target advanced international R&D, help the Central Region build dominant industry clusters, and bolster the global competitiveness and influence of these key industrial chains.

It had already nurtured over 120 national-level "little giant" enterprises. The fact that Wu’s Pharmaceutical Company, built around Wu Ting’s research project, had secured an investment from the Fan City Mother Fund sent an undeniable signal to the market.

This was a high-quality company with immense commercial potential and advanced research capabilities, endorsed and funded by a government fund!

Dean Tang was also surprised; he hadn’t realized Wu Ting’s research project had such commercial potential!

After Tang Shengjie spoke with Dean Tang, the Fan City Mother Fund dispatched a dedicated team to visit Wu Ting.

In the CEO’s office of Wu’s Pharmaceutical Company—an enterprise single-handedly established by Deng Feifei—Wu Ting, in his capacity as founder and chairman, received the team from the Fan City Mother Fund.

Deng Feifei, his perfect partner and the manager responsible for technology commercialization, also attended the meeting.

With Tang Shengjie championing the deal from the top, the business negotiations were, of course, exceptionally smooth, and an agreement was quickly reached.

The Fan City Mother Fund established a subsidiary fund and, through it, invested 10 million in Wu’s Pharmaceutical Company!

Also for a 10% stake!

After the agreement was reached, the next step was to attend the official signing ceremony.

This signing ceremony was going to be a truly top-tier event. All sorts of bigwigs would be in attendance to witness the signing!

Wu Ting was thrilled about this opportunity.

This wasn’t just about securing a ten-million investment; it was about gaining policy support. An endorsement from a government fund meant a great deal. Coupled with the operational capabilities of the Jin Pharmaceutical Group, he believed that after this signing ceremony, the company would ascend to a whole new level.

After the amicable agreement was finalized, Wu Ting and Deng Feifei saw the team from the mother fund out.

Back in the CEO’s office, Wu Ting felt a wave of emotion. ’Without even realizing it, I’ve become the chairman of a future "little giant" enterprise. And crucially, I still own a 51% stake. Once the business is on the right track, my wealth is going to grow exponentially.’

Inside the CEO’s office, Wu Ting and Deng Feifei exchanged a look of mutual admiration.

"President Deng, thank you for all your hard work. And congratulations to us—the company is finally getting on the right track!"

Deng Feifei’s stunning face, complemented by her professional attire, exuded the intellectual beauty of a female senior executive. The makeup she had worn to receive the team from the mother fund gave her an air of sophistication.

Her elegant hairstyle revealed a fair, delicate neck. Her exquisite ears were adorned with jeweled earrings worth hundreds of thousands, perfectly complementing her masterful business skills.

Deng Feifei was truly worthy of being the business successor that Jin Yihong had painstakingly cultivated. Her talent and charisma were both top-tier.

Wu Ting had never expected to have such a business partner.

Deng Feifei responded to Wu Ting with equal enthusiasm and admiration.

"President Wu, I should say the honor is all mine. To be able to start a business with a scientist and surgeon as young and brilliant as you... It fills me with passion. I feel energized every single day..."

Deng Feifei looked at Wu Ting with a fervent gaze and smiled faintly.

"President Wu, after the signing is complete, the first batch of products being manufactured for us at the Jin Pharmaceutical Group’s factories can be rolled out for sale."

"During this time, I will also temporarily transfer a sales team from the Jin Pharmaceutical Group to start signing partnership deals..."

Deng Feifei had planned the next steps of the business operations far in advance, viewing her collaboration with Wu Ting as an extremely important Chapter in her career.

...

...

「Jinggang University Affiliated First Hospital.」

Dean Song convened a last-minute meeting, calling together Shen Xiaofei, the Director of Hepatobiliary Surgery; Shen Siyuan, the Deputy Director of Cardiac Surgery; Shen Guofeng, the Director of the Emergency Department; and Fu Jinfen, the Director of Hepatic Tumor Surgery.

For some time now, Dean Song had been observing Wu Ting’s performance, and he became determined not to let such a talent slip away.

His admiration for Wu Ting reached its peak, especially after the recent collaborative exchange with the three top pharmaceutical companies and the leading figures in immunology.

In the conference room, Dean Song looked at everyone and got straight to the point.

"I’ve called you all here for this short meeting today to ask for your opinions on inviting Dr. Wu Ting to join us at Jinggang University Affiliated First Hospital..."

Hearing Dean Song get to the point so directly, the department directors were all quite surprised, but they wholeheartedly supported the idea.

"Wu Ting’s performance recently has been plain for all to see, especially in the interdisciplinary field of immunology and hepatitis B-related primary liver cancer."

"According to the latest information I’ve received, Wu Ting’s project will be receiving funding from the HHMI Research Institute. It will also get funding from the Fan City Mother Fund, and our own university’s mother fund will also be investing 10 million... Director Han Yu has also confirmed that he will be helping Wu Ting’s team apply for a key project grant from the National Natural Science Foundation, which also comes with 10 million in funding..."